Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
about
Opioid agonist treatment for pharmaceutical opioid dependent peopleBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence2012 Update in addiction medicine for the generalistA pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersA Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid AddictionDiscontinuation of buprenorphine maintenance therapy: perspectives and outcomesUpdate on Barriers to Pharmacotherapy for Opioid Use Disorders.The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.Effects of Mindfulness-Oriented Recovery Enhancement on reward responsiveness and opioid cue-reactivity.Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.Laboratory-induced cue reactivity among individuals with prescription opioid dependence.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceReasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain.Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial.A Mixed-Method Analysis of Reports on 100 Cases of Improper Prescribing of Controlled SubstancesImplementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sampleCue-induced craving in dependence upon prescription opioids and heroin.Medication-assisted therapy for opioid addiction.Emerging adult age status predicts poor buprenorphine treatment retention.Rapid opiate detoxification and antagonist induction under general anaesthesia or intravenous sedation is humane, sometimes essential and should always be an option. Three illustrative case reports involving diabetes and epilepsy and a review of theOpioid therapy for chronic pain in the United States: promises and perilsImproving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.Predictors of dropout from inpatient opioid detoxification with buprenorphine: a chart reviewBuprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination usersDenial of urinalysis-confirmed opioid use in prescription opioid dependenceThe multi-site prescription opioid addiction treatment study: 18-month outcomesPrescription drug abuse: from epidemiology to public policyOpioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.Buprenorphine implant for opioid addictionInitial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent populationCommentary on Burns et al. (2015): retention in buprenorphine treatmentLong-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment StudyBaseline characteristics of patients predicting suitability for rapid naltrexone induction.
P2860
Q24185775-95D87FFC-46FE-4C57-9D3A-651809ECE98FQ24200539-D56E9FA7-8A79-43FE-BC3D-8476C0D29658Q26864774-523E4612-7888-4DD3-B3E3-C7F518D6318EQ27000732-ACB7C3E2-C8EA-470F-9779-5179BE648661Q28069995-A19FCFDF-79D7-43F3-BE2E-78B8EF28A5A4Q28082657-8BC3B73B-C6C0-40AE-B3EA-DDBD61871850Q30234408-D0E8BC9F-2D2C-410C-B9C4-2D4F8EF649BCQ30239085-48AE7B77-2949-4A7C-AA6D-901396980A73Q30252443-54C82680-D72A-4B41-9600-B68A1947A21EQ30437184-BA0A744F-C4C8-4869-9A38-1B4F3243237FQ30585000-97AA616B-2C1E-42C7-BC29-C84AC380B976Q33740800-1C440763-F139-4187-92D6-CF332BA3F2BAQ33751060-0739872C-8251-4095-B2FC-C0C9DC6982A5Q33761482-2B3A8B7A-8B5B-4180-978A-8EEBE7017F02Q33783250-B0661635-CF01-4436-BB64-AD2B11C0C7DBQ33818740-03AEBED2-299B-464F-8DAF-EA6A50D6F94CQ33824759-BF627982-93DB-4B3B-BF15-D45791F221C2Q33836102-25CE7B43-61F1-4810-AB77-B8DE65F6F9BDQ33859272-FC4A3EE6-CC05-4A54-BB2F-1CAB02090C7AQ33949888-AEDEC56C-D64B-4612-8074-42D870847A72Q34040286-ED9DC7B8-F1EB-4ED6-947A-B65B5207CF73Q34119478-6D364A24-DAB3-45B1-9A94-46789528ECDDQ34180281-466E0A7F-3F2E-404A-BB7F-9F81B495F10FQ34247772-257B72EA-DA9F-4FCC-939C-5ECEFCA7135AQ34269194-177E7A1A-37D7-4C07-8498-2AE923A38128Q34371727-6D191F3D-D320-448F-A38F-3561CBCD64A6Q34377491-FA0F94B4-878C-4CDF-91FA-04DB22705F16Q34404288-37B21B71-D21C-44AD-83C4-1031711F90F1Q34501351-B9DBBD7D-4CAA-45C5-AB00-42270C5D8E3EQ34602600-1D8111BD-30B5-4E78-B096-2286D0711FD3Q34602901-1A051265-067D-4E8F-AF8B-BC89EFEE223FQ34602946-1E3E8C1E-09B6-47EF-8477-46A6E7FCB519Q34603363-4A20C525-09DE-478E-9561-E4034C51B545Q34615450-6172B0B3-A4A2-4113-85C0-5B43A27D1F5CQ34620651-0803E47C-1416-48D3-AEC3-78F032D96F93Q34820000-DBDAEC78-4DAB-4840-82D8-E11410ABD512Q35154999-609E9D8B-DBFE-43BE-90D9-945201FB83A0Q35198995-C949898C-14CF-474E-83F4-61AD42F4CE02Q35532106-E7913D48-CA99-4526-B0EB-8F73E132F2C8Q35834292-3FC328BE-EAA7-4C37-8F7C-1A1CE56FE49A
P2860
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Adjunctive counseling during b ...... e randomized controlled trial.
@ast
Adjunctive counseling during b ...... e randomized controlled trial.
@en
type
label
Adjunctive counseling during b ...... e randomized controlled trial.
@ast
Adjunctive counseling during b ...... e randomized controlled trial.
@en
prefLabel
Adjunctive counseling during b ...... e randomized controlled trial.
@ast
Adjunctive counseling during b ...... e randomized controlled trial.
@en
P2093
P2860
P50
P1433
P1476
Adjunctive counseling during b ...... e randomized controlled trial.
@en
P2093
Albert L Hasson
Andrzej S Kosinski
Deborah L Haller
Elinore F McCance-Katz
Eugene C Somoza
Hilary S Connery
Jeffrey Selzer
John Gardin
Margaret L Griffin
Marilyn Byrne
P2860
P304
P356
10.1001/ARCHGENPSYCHIATRY.2011.121
P407
P577
2011-11-07T00:00:00Z